

Public Dashboard

Reporting Period: July 2023 - June 2024 (Current Period); July 2022 – June 2023 (Prior Period)

Includes all covered plan participants (Active, Non-Medicare Retirees and Medicare Retirees) unless otherwise noted




Table of Contents

- Page 3 Enrollment (Actives)
- Page 4 Enrollment (Retirees)
- Page 5 Plan Paid By Setting
- Page 9 Plan Paid By Age Band and Gender
- Page 13 Emergency Room Visits
- Page 17 Top 15 Drugs
- Page 21 Top 15 Prescription Drug Disease Indications
- Page 25 Top 15 Diagnosis Categories for Medical Claims
- Page 29 Distribution of Claims By Membership



Enrollment: Actives *July* 2023 – *June* 2024

Average Employee and Dependent Counts



Average Employee and Dependent Counts

Line of Business	Employee Count	Dependent Count	Total Count	PEPM ¹
Partnership	25,334	31,257	56,590	\$1,600.87 ²
State	49,745	68,228	117,973	\$1,489.80
Total	75,078	99,485	174,563	\$1,527.28




¹ Per Employee Per Month

² Partnership is higher due to membership located in counties that have a higher average cost of care, Regional pricing adjustments account for this disparity.

Enrollment: Retirees *July* 2023 – *June* 2024

Average Retiree and Dependent Counts




Average Retiree and Dependent Counts

Status	Retiree Count	Dependent Count	Total Count	PEPM ¹
Non-Medicare Retirees	17,236	16,062	33,298	\$1,670
Medicare Retirees	43,988	15,877	59,864	\$1,436



Plan Paid By Setting – State Plan Active Population







Plan Paid By Setting — State Plan Non-Medicare Retirees













Plan Paid By Setting – State Plan Medicare Retirees






Plan Paid By Setting — Partnership Plan (includes retirees)








Plan Paid By Age and Gender – State Plan Active Population *July* 2023 – *June* 2024







Plan Paid By Age and Gender – State Plan Non-Medicare July 2023 – June 2024



Plan Paid By Age and Gender – State Plan Medicare Retirees *July* 2023 – *June* 2024



Plan Paid By Age and Gender — Partnership Plan (incl. retirees) July 2023 – June 2024







Emergency Room Visits - State Plan Active Population

July 2023 – June 2024 (Current Period); July 2022 – June 2023 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	33,003	280
Prior	30,754	272







Emergency Room Visits - State Plan Non-Medicare Retirees

July 2023 – June 2024 (Current Period); July 2022 – June 2023 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	11,183	336
Prior	11,982	330







Emergency Room Visits - State Plan Medicare Retirees

July 2023 – June 2024 (Current Period); July 2022 – June 2023 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	32,998	551
Prior	28,467	485







Emergency Room Visits - Partnership Plan (includes retirees)

July 2023 – June 2024 (Current Period); July 2022 – June 2023 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	16,948	284
Prior	16,411	256





Top 15 Drugs – State Plan Active Population July 2023 – June 2024 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	OZEMPIC	Diabetes	\$13,870,645	30,163	\$460
2	DUPIXENT	Skin Disorders	\$8,609,525	3,720	\$2,314
3	SKYRIZI	Psoriasis	\$7,362,449	892	\$8,254
4	STELARA	Psoriasis	\$5,414,938	798	\$6,786
5	MOUNJARO	Diabetes	\$4,897,164	10,050	\$487
6	STRENSIQ	Rare Disorders	\$4,695,510	58	\$80,957
7	HUMIRA PEN	Autoimmune Disease	\$4,674,587	2,021	\$2,313
8	TRIKAFTA	Cystic Fibrosis	\$4,317,756	205	\$21,062
9	VYVANSE	ADHD/Narcolepsy	\$3,186,026	8,632	\$369
10	VERZENIO	Oncology	\$1,992,263	214	\$9,310
11	NURTEC	Migraine	\$1,987,852	3,052	\$651
12	RINVOQ	Autoimmune Disease	\$1,924,977	598	\$3,219
13	XOLAIR	Asthma/COPD	\$1,883,497	942	\$1,999
14	VRAYLAR	Mental Health/Neurological Disorders	\$1,801,478	1,269	\$1,420
15	BIKTARVY	Viral Infections/HIV AIDS	\$1,759,805	639	\$2,754

Top 15 Drugs – State Plan Non-Medicare Retirees *July 2023 – June 2024 By Plan Paid*

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	OZEMPIC	Diabetes	\$5,156,907	10,606	\$486
2	DUPIXENT	Skin Disorders	\$2,385,960	1,031	\$2,314
3	SKYRIZI	Psoriasis	\$2,141,994	236	\$9,076
4	MOUNJARO	Diabetes	\$2,069,754	3,981	\$520
5	HUMIRA PEN	Autoimmune Disease	\$1,849,577	811	\$2,281
6	STELARA	Psoriasis	\$1,480,488	236	\$6,273
7	TRIKAFTA	Cystic Fibrosis	\$1,198,222	67	\$17,884
8	XOLAIR	Asthma/COPD	\$1,008,530	490	\$2,058
9	VERZENIO	Oncology	\$1,000,403	107	\$9,350
10	BIKTARVY	Viral Infections/HIV AIDS	\$976,455	326	\$2,995
11	TRULICITY	Diabetes	\$819,012	1,535	\$534
12	OTEZLA	Autoimmune Disease	\$810,767	417	\$1,944
13	ELIQUIS	Blood Disorders	\$785,499	1,828	\$430
14	HEMLIBRA	Hemophilia	\$785,027	20	\$39,251
15	VYVANSE	ADHD/Narcolepsy	\$752,440	1,981	\$380

Top 15 Drugs – State Plan Medicare Retirees *July 2023 – June 2024 By Plan Paid*

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	ELIQUIS	Blood Disorders	\$34,924,631	26,638	\$1,311
2	OZEMPIC	Diabetes	\$25,472,954	14,881	\$1,712
3	JARDIANCE	Diabetes	\$16,454,802	10,085	\$1,632
4	HUMIRA PEN	Autoimmune Disease	\$14,065,002	991	\$14,193
5	VYNDAMAX	Cardiovascular/Heart Disease	\$12,394,339	259	\$47,855
6	XARELTO	Blood Disorders	\$11,831,123	8,194	\$1,444
7	REVLIMID	Oncology	\$10,287,986	505	\$20,372
8	DUPIXENT	Skin Disorders	\$9,894,716	2,023	\$4,891
9	TRULICITY	Diabetes	\$8,895,412	4,693	\$1,895
10	STELARA	Psoriasis	\$8,714,831	290	\$30,051
11	TRELEGY ELLIPTA	Asthma/COPD	\$8,371,031	7,044	\$1,188
12	JANUVIA	Diabetes	\$8,351,316	5,439	\$1,535
13	MOUNJARO	Diabetes	\$7,708,614	4,761	\$1,619
14	SKYRIZI	Psoriasis	\$7,604,939	319	\$23,840
15	IMBRUVICA	Oncology	\$7,463,239	334	\$22,345

Top 15 Drugs – Partnership Plan (includes retirees) July 2023 – June 2024 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	OZEMPIC	Diabetes	\$6,261,491	11,785	\$531
2	DUPIXENT	Skin Disorders	\$4,191,567	1,719	\$2,438
3	STELARA	Psoriasis	\$3,284,579	370	\$8,877
4	HUMIRA PEN	Autoimmune Disease	\$3,019,861	1,050	\$2,876
5	SKYRIZI	Psoriasis	\$2,869,018	330	\$8,694
6	ELIQUIS	Blood Disorders	\$2,571,390	3,329	\$772
7	MOUNJARO	Diabetes	\$2,342,966	4,077	\$575
8	XTANDI	Oncology	\$1,663,745	117	\$14,220
9	VYVANSE	ADHD/Narcolepsy	\$1,351,552	3,953	\$342
10	TRULICITY	Diabetes	\$1,246,347	1,571	\$793
11	ENBREL SURECLICK	Autoimmune Disease	\$1,105,045	358	\$3,087
12	XARELTO	Blood Disorders	\$1,087,032	1,628	\$668
13	JARDIANCE	Diabetes	\$1,083,557	688	\$1,575
14	MEPSEVII	Rare Disorders	\$1,014,882	12	\$84,574
15	ENTRESTO	Cardiovascular/Heart Disease	\$1,004,721	847	\$1,186



Top 15 Prescription Drug Disease Indications State Plan Active Population

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Diabetes	\$25,641,883	85,795	\$299
2	Oncology	\$18,205,035	6,294	\$2,892
3	Autoimmune Disease	\$17,317,327	8,616	\$2,010
4	Psoriasis	\$16,298,897	4,166	\$3,912
5	Skin Disorders	\$13,421,871	62,341	\$215
6	ADHD/Narcolepsy	\$10,388,073	51,183	\$203
7	Multiple Sclerosis/Neuromuscular Disorders	\$9,383,232	1,548	\$6,062
8	Asthma/COPD	\$8,261,600	65,047	\$127
9	Rare Disorders	\$6,658,771	1,550	\$4,296
10	Viral Infections/HIV AIDS	\$5,876,679	3,397	\$1,730
11	Migraine	\$5,362,518	20,297	\$264
12	Cystic Fibrosis	\$4,823,628	323	\$14,934
13	Vaccines/Immunizing Agents	\$4,693,952	39,745	\$118
14	Depression	\$4,649,308	92,674	\$50
15	Mental Health/Neurological Disorders	\$4,586,366	15,000	\$306



Top 15 Prescription Drug Disease Indications State Plan Non-Medicare Retirees

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Diabetes	\$11,760,209	38,553	\$305
2	Oncology	\$8,739,063	3,067	\$2,849
3	Autoimmune Disease	\$7,589,076	3,698	\$2,052
4	Psoriasis	\$5,115,175	1,322	\$3,869
5	Skin Disorders	\$3,947,595	20,923	\$189
6	Asthma/COPD	\$3,902,117	23,188	\$168
7	Multiple Sclerosis/Neuromuscular Disorders	\$3,336,258	685	\$4,870
8	ADHD/Narcolepsy	\$2,642,588	11,613	\$228
9	Lipid/Cholesterol Disorders	\$2,440,872	39,649	\$62
10	Viral Infections/HIV AIDS	\$2,426,643	1,194	\$2,032
11	Vaccines/Immunizing Agents	\$2,192,170	16,423	\$133
12	Depression	\$2,174,200	34,641	\$63
13	Seizure Disorder	\$2,121,538	16,184	\$131
14	Blood Disorders	\$2,114,190	5,252	\$403
15	Cardiovascular/Hypertension	\$1,983,238	66,722	\$30



Top 15 Prescription Drug Disease Indications State Plan Medicare Retirees

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Diabetes	\$114,193,486	114,016	\$1,002
2	Oncology	\$96,390,460	13,807	\$6,981
3	Blood Disorders	\$56,861,785	54,988	\$1,034
4	Autoimmune Disease	\$44,941,279	6,758	\$6,650
5	Asthma/COPD	\$34,004,588	77,378	\$439
6	Cardiovascular/Heart Disease	\$27,811,442	21,795	\$1,276
7	Psoriasis	\$27,678,753	1,977	\$14,000
8	Vaccines/Immunizing Agents	\$26,089,090	89,551	\$291
9	Skin Disorders	\$15,053,743	43,164	\$349
10	Multiple Sclerosis/Neuromuscular Disorders	\$13,196,948	1,242	\$10,626
11	Lipid/Cholesterol Disorders	\$12,980,888	179,151	\$72
12	Overactive Bladder/Urinary Incontinence	\$11,190,239	17,460	\$641
13	Cardiovascular/Hypertension	\$9,101,776	333,188	\$27
14	Ophthalmology	\$7,966,937	12,831	\$621
15	Anti-Infectives	\$7,822,894	110,411	\$71

Top 15 Prescription Drug Disease Indications Partnership Plan (includes retirees)

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Oncology	\$16,321,123	4,223	\$3,865
2	Diabetes	\$16,138,007	42,349	\$381
3	Autoimmune Disease	\$10,735,047	4,674	\$2,297
4	Psoriasis	\$7,862,739	1,851	\$4,248
5	Skin Disorders	\$6,340,080	29,118	\$218
6	Asthma/COPD	\$5,267,068	30,941	\$170
7	Vaccines/Immunizing Agents	\$4,445,434	22,709	\$196
8	Blood Disorders	\$4,316,481	8,327	\$518
9	ADHD/Narcolepsy	\$4,114,039	24,099	\$171
10	Rare Disorders	\$3,752,089	942	\$3,983
11	Multiple Sclerosis/Neuromuscular Disorders	\$3,625,314	791	\$4,583
12	Cardiovascular/Heart Disease	\$3,381,529	3,188	\$1,061
13	Viral Infections/HIV AIDS	\$2,525,743	1,546	\$1,634
14	Mental Health/Neurological Disorders	\$2,457,749	7,859	\$313
15	Lipid/Cholesterol Disorders	\$2,437,708	42,500	\$57

Top 15 Medical Diagnosis Categories State Plan Active Population

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care	\$ 29,187,549.80
2	Encounter for screening for malignant neoplasms	\$ 29,117,637.36
3	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 24,372,583.42
4	Multiple sclerosis	\$ 15,819,945.21
5	Dorsalgia	\$ 15,062,144.22
6	Other anxiety disorders	\$ 14,353,355.47
7	Major depressive disorder, recurrent	\$ 13,238,469.80
8	Reaction to severe stress, and adjustment disorders	\$ 12,346,375.68
9	Other sepsis	\$ 11,719,432.90
10	Pervasive developmental disorders	\$ 11,526,434.88
11	Other joint disorder, not elsewhere classified	\$ 11,094,228.95
12	Liveborn infants according to place of birth and type of delivery	\$ 11,074,612.60
13	Encounter for other special examination without complaint, suspected or reported diagnosis	\$ 10,333,659.73
14	Abdominal and pelvic pain	\$ 9,696,233.94
15	Sleep disorders	\$ 9,385,747.84

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories State Plan Non-Medicare Retirees

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care	\$ 20,096,184.15
2	Encounter for screening for malignant neoplasms	\$ 12,541,319.58
3	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 6,342,859.11
4	Dorsalgia	\$ 5,900,617.90
5	Osteoarthritis of knee	\$ 5,841,900.04
6	Alcohol related disorders	\$ 5,015,705.21
7	Other sepsis	\$ 4,780,037.90
8	Osteoarthritis of hip	\$ 4,663,986.03
9	Multiple sclerosis	\$ 4,554,626.70
10	Atrial fibrillation and flutter	\$ 4,490,781.02
11	Other joint disorder, not elsewhere classified	\$ 4,410,344.94
12	Major depressive disorder, recurrent	\$ 4,046,049.99
13	Sleep disorders	\$ 3,911,028.76
14	Type 2 diabetes mellitus	\$ 3,848,453.21
15	Other spondylopathies	\$ 3,722,163.78

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories State Plan Medicare Retirees

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care	\$ 39,971,256.01
2	Other sepsis	\$ 25,068,891.19
3	Osteoarthritis of knee	\$ 15,901,465.88
4	Atrial fibrillation and flutter	\$ 14,773,146.73
5	Type 2 diabetes mellitus	\$ 14,548,092.74
6	Other retinal disorders	\$ 12,635,412.31
7	Chronic kidney disease (CKD)	\$ 12,237,649.11
8	Dorsalgia	\$ 10,925,341.24
9	Chronic ischemic heart disease	\$ 10,522,083.93
10	Encounter for screening for malignant neoplasms	\$ 10,248,690.59
11	Other spondylopathies	\$ 9,922,299.62
12	Age-related cataract	\$ 9,901,036.12
13	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 8,676,913.21
14	Other joint disorder, not elsewhere classified	\$ 8,643,162.05
15	Fracture of femur	\$ 8,476,757.65

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories Partnership Plan (includes retirees)

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care	\$ 20,641,148.42
2	Encounter for screening for malignant neoplasms	\$ 15,112,084.92
3	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 12,732,186.42
4	Other anxiety disorders	\$ 7,927,312.17
5	Liveborn infants according to place of birth and type of delivery	\$ 7,879,106.05
6	Dorsalgia	\$ 7,548,922.12
7	Multiple sclerosis	\$ 7,392,420.91
8	Other sepsis	\$ 6,899,776.55
9	Osteoarthritis of knee	\$ 5,849,406.28
10	Other joint disorder, not elsewhere classified	\$ 5,718,913.20
11	Reaction to severe stress, and adjustment disorders	\$ 5,576,075.63
12	Encounter for other special examination without complaint, suspected or reported diagnosis	\$ 5,214,900.65
13	Major depressive disorder, recurrent	\$ 4,747,713.60
14	Abdominal and pelvic pain	\$ 4,616,113.16
15	Atrial fibrillation and flutter	\$ 4,384,261.80


¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.

As Partnership retiree membership increases, they will be reported separately.




July 2023 – June 2024 By Plan Paid– State Plan Active Population






July 2023 – June 2024 By Plan Paid– State Plan Non-Medicare Population






July 2023 – June 2024 By Plan Paid– State Plan Medicare Population





July 2023 – June 2024 By Plan Paid– Partnership Plan (includes retirees)



¹ Per Member Per Month As Partnership retiree membership increases, they will be reported separately.